DiaCarta

DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.
Type
Private
HQ
Richmond, US
Employees
28 (est)-3%

Key People at DiaCarta

Aiguo Zhang

Aiguo Zhang

President & CEO
Paul Okunieff

Paul Okunieff

CMO

DiaCarta Locations

Richmond, US

DiaCarta Metrics

DiaCarta Summary

Total Funding

$8 M

Latest funding size

$8 M

Time since last funding

almost 2 years

Investors

Market Position – Health, biotech, hospitals, pharma, clinical research, clinics, diagnostics

DiaCarta Company Life

You may also be interested in